Font Size: a A A
Keyword [EGFR-T790M]
Result: 1 - 20 | Page: 1 of 2
1. Screening, Design And Activity Study Of Anti - Lung Cancer Drugs Targeted With Protein Tyrosine Kinase Family
2. CEGF06Inhibit EGFRT790M And Its Anti-tumor Research
3. Predictive Role Of Pretreatment EGFR T790M Mutation On TKI Therapy In NSCLC Patients-a Meta-analysis
4. The Research On Change Of Chemosensitivity Of Gefitinib-resistant Lung Adenocarcinoma Cell Caused By EGFR-T790M Mutation
5. The Comparision Of Methods For The Detection Of EGFR Gene Mutations In Serum Of Lung Cancer Patients
6. Investigation On The EGFR-TKI Resistance Mechanisms Of NSCLC With EGFR Mutations In Vitro
7. The Esteblishment Of EGFR And PI3Ks High Throughput Screening
8. Clinicopathological Characteristics Of Non-small Cell Lung Cancer Patients With Primary Concomitant EGFR T790M Mutation
9. A Comparison Of Two Methods For Detecting EGFR T790M Status From Advanced NSCLC Patients With Acquired EGFR-TKI Resistance And Clinical Analysis
10. Filamin A Is Correlated With Sensitivity To Third Generation EGFR-TKIs In Lung Adenocarcinoma H1975 Cell With EGFR T790M Mutation
11. Up-regulation Of The Hippo Pathway Effector TAZ Renders Lung Adenocarcinoma Cells Harboring EGFR-T790M Mutation Resistant To Gefitinib
12. Characteristics And Survival In Non-small Cell Lung Cancer Patients Harbored Primary And Acquired EGFR T790M Mutation
13. Clinical Study Of T790M Mutation In Blood Of Non-small Cell Lung Cancer Patients With EGFR-TKI Resistance Using NGS Technology
14. Mechanism Of BPI-15086 On EGFR-T790M In Vitro
15. A Preclinical Study Of Osimertinib(AZD9291) Combined With Radiation For EGFR T790M Mutant Nonsmall Cell Lung Cancer
16. Correlation Between EGFR T790M And Prognosis Of Advanced Lung Adenocarcinoma
17. The Association Between BIM Deletion Polymorphism And Therapeutic Efficacy In Advanced EGFR T790M NSCLC With Osimertinib
18. Mechanism Of BPI-15086 On EGFR-T790M In Vitro
19. The Efficacy And Safety Of Patients With EGFR-T790M Mutation-positive Advanced Non-small Cell Lung Cancer With Different Sources Osimertinib Treatment
20. Analysis Of EGFR T790M Mutation Rate And Related Characteristics After First-line Treatment Of Advanced Non-small Cell Lung Cancer With Sensitive Mutations
  <<First  <Prev  Next>  Last>>  Jump to